Often underappreciated for its immensity, Indonesia has approximately 250 million people, which makes it the world’s fourth most populous country. Indonesia also plays an outsized role in the region’s economic activity, as its economy is the largest in the Association of South East Asian Nations (ASEAN). Indonesia may be classified as a lower-middle income country, but it offers vast potential in terms of commercial opportunity, particularly in pharmaceuticals. From 2007 to 2013, Indonesia’s pharmaceutical industry grew by 85 percent, including 7% in 2014 alone, and is now valued at $6 billion. Growth is forecasted to rise to 12% in 2015 and to continue through 2018. As Indonesia’s market for pharmaceuticals expands and deepens, domestic and multinational players are positioning themselves to capitalize on emerging opportunities.

Featuring exclusive interviews with:

Ministry of Health, Republic of Indonesia – Dr. Maura Linda Sitanggang, Director General of Pharmaceutical Services and Medical Devices
National Board Indonesian Pharmaceutical Association (GP. Farmasi Indonesia) – Dr. Johannes Setijono, Chairman, National Board
National Agency for Drug and Food Control (BPOM) – Roy Sparringa, PhD., Chairman
Menjangan Sakti, Mensa Group – Jonathan Sudharta, Managing Director
Interbat – Derrick Budi Sukamto, Vice President
Combiphar – Michael Wanandi, President Director
Tigaka Distrindo Perkasa (TDP) – Thomas Ricky Harsono, Chief Executive Officer
Ekacitta Dian Persada – Dr. Setiawan Nugroho, President Director
Genero Pharmaceuticals – Alfons Sindupranata, Managing Director
DSM Nutritional Products Indonesia – Haeri Roh-Schmidt, General Manager
Pharos – Dr. Andre Arief Lembong, Chairman
Soho Global Health – Rogelio C. la O’Jr. (Cooey), President Director & Chief Executive Officer